Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
43
FBRX Quote, Financials, Valuation and Earnings
Last price:
$25.56
Seasonality move
:
1.35%
Day range:
$23.47 - $25.76
52-week range:
$4.90 - $35.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.58x
Volume:
241.6K
Avg. volume:
232.7K
1-year change:
248.03%
Market cap:
$340.5M
Revenue:
--
EPS (TTM):
-$4.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FBRX
Forte Biosciences, Inc.
|
-- | -$1.14 | -- | -3.01% | $63.75 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
AGEN
Agenus, Inc.
|
$129.5M | $1.80 | 34.29% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$66.6M | -$1.01 | -87.74% | -73.49% | $81.09 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FBRX
Forte Biosciences, Inc.
|
$25.58 | $63.75 | $340.5M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $125.6M | -- | $0.00 | 0% | 0.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 136.93x | $0.00 | 0% | 11.11x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$61.03 | $81.09 | $8.3B | 38.49x | $0.00 | 0% | 7.46x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FBRX
Forte Biosciences, Inc.
|
-- | 3.183 | -- | 7.19x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
525.02% | -0.070 | 321.54% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 1.895 | 7.54% | 3.27x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FBRX
Forte Biosciences, Inc.
|
-$17K | -$18.4M | -91.42% | -91.42% | -- | -$14.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$33.6M | $14.4M | -3.83% | -- | 42.1% | -$16.6M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
Forte Biosciences, Inc. vs. Competitors
-
Which has Higher Returns FBRX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Forte Biosciences, Inc.'s net margin of 96.33%. Forte Biosciences, Inc.'s return on equity of -91.42% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital FBRXForte Biosciences, Inc.-- -$0.99 $84.1M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About FBRX or ACAD?
Forte Biosciences, Inc. has a consensus price target of $63.75, signalling upside risk potential of 149.22%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that Forte Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Forte Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBRXForte Biosciences, Inc.5 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is FBRX or ACAD More Risky?
Forte Biosciences, Inc. has a beta of 3.202, which suggesting that the stock is 220.242% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock FBRX or ACAD?
Forte Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Forte Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBRX or ACAD?
Forte Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Forte Biosciences, Inc.'s net income of -$17.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Forte Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Forte Biosciences, Inc. is -- versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBRXForte Biosciences, Inc.-- -- -- -$17.7M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns FBRX or AGEN?
Agenus, Inc. has a net margin of -- compared to Forte Biosciences, Inc.'s net margin of -31.03%. Forte Biosciences, Inc.'s return on equity of -91.42% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FBRXForte Biosciences, Inc.-- -$0.99 $84.1M AGENAgenus, Inc.98.26% -$0.30 $57M -
What do Analysts Say About FBRX or AGEN?
Forte Biosciences, Inc. has a consensus price target of $63.75, signalling upside risk potential of 149.22%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Agenus, Inc. has higher upside potential than Forte Biosciences, Inc., analysts believe Agenus, Inc. is more attractive than Forte Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBRXForte Biosciences, Inc.5 0 0 AGENAgenus, Inc.2 1 0 -
Is FBRX or AGEN More Risky?
Forte Biosciences, Inc. has a beta of 3.202, which suggesting that the stock is 220.242% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.
-
Which is a Better Dividend Stock FBRX or AGEN?
Forte Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Forte Biosciences, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBRX or AGEN?
Forte Biosciences, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Forte Biosciences, Inc.'s net income of -$17.7M is lower than Agenus, Inc.'s net income of -$10.6M. Notably, Forte Biosciences, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Forte Biosciences, Inc. is -- versus 0.86x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBRXForte Biosciences, Inc.-- -- -- -$17.7M AGENAgenus, Inc.0.86x -- $34.2M -$10.6M
-
Which has Higher Returns FBRX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Forte Biosciences, Inc.'s net margin of 16.99%. Forte Biosciences, Inc.'s return on equity of -91.42% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital FBRXForte Biosciences, Inc.-- -$0.99 $84.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About FBRX or ALNY?
Forte Biosciences, Inc. has a consensus price target of $63.75, signalling upside risk potential of 149.22%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Forte Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Forte Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBRXForte Biosciences, Inc.5 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is FBRX or ALNY More Risky?
Forte Biosciences, Inc. has a beta of 3.202, which suggesting that the stock is 220.242% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock FBRX or ALNY?
Forte Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Forte Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBRX or ALNY?
Forte Biosciences, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Forte Biosciences, Inc.'s net income of -$17.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Forte Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 136.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Forte Biosciences, Inc. is -- versus 11.11x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBRXForte Biosciences, Inc.-- -- -- -$17.7M ALNYAlnylam Pharmaceuticals, Inc.11.11x 136.93x $1.1B $186.4M
-
Which has Higher Returns FBRX or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Forte Biosciences, Inc.'s net margin of 10.7%. Forte Biosciences, Inc.'s return on equity of -91.42% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital FBRXForte Biosciences, Inc.-- -$0.99 $84.1M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About FBRX or ARWR?
Forte Biosciences, Inc. has a consensus price target of $63.75, signalling upside risk potential of 149.22%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.09 which suggests that it could grow by 32.87%. Given that Forte Biosciences, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Forte Biosciences, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBRXForte Biosciences, Inc.5 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 3 0 -
Is FBRX or ARWR More Risky?
Forte Biosciences, Inc. has a beta of 3.202, which suggesting that the stock is 220.242% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.261, suggesting its more volatile than the S&P 500 by 26.13%.
-
Which is a Better Dividend Stock FBRX or ARWR?
Forte Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Forte Biosciences, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBRX or ARWR?
Forte Biosciences, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Forte Biosciences, Inc.'s net income of -$17.7M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Forte Biosciences, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 38.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Forte Biosciences, Inc. is -- versus 7.46x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBRXForte Biosciences, Inc.-- -- -- -$17.7M ARWRArrowhead Pharmaceuticals, Inc.7.46x 38.49x $264M $28.2M
-
Which has Higher Returns FBRX or SVRA?
Savara, Inc. has a net margin of -- compared to Forte Biosciences, Inc.'s net margin of --. Forte Biosciences, Inc.'s return on equity of -91.42% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital FBRXForte Biosciences, Inc.-- -$0.99 $84.1M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About FBRX or SVRA?
Forte Biosciences, Inc. has a consensus price target of $63.75, signalling upside risk potential of 149.22%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Forte Biosciences, Inc. has higher upside potential than Savara, Inc., analysts believe Forte Biosciences, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBRXForte Biosciences, Inc.5 0 0 SVRASavara, Inc.6 0 0 -
Is FBRX or SVRA More Risky?
Forte Biosciences, Inc. has a beta of 3.202, which suggesting that the stock is 220.242% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock FBRX or SVRA?
Forte Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Forte Biosciences, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBRX or SVRA?
Forte Biosciences, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Forte Biosciences, Inc.'s net income of -$17.7M is higher than Savara, Inc.'s net income of -$32.2M. Notably, Forte Biosciences, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Forte Biosciences, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBRXForte Biosciences, Inc.-- -- -- -$17.7M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
